Attendee search 

Tasly Pharmaceutical was founded in 1994 and listed in Shanghai Stock Exchange in 2002, which is a pioneer and leading player in China's pharmaceutical industry focusing on developing, manufacturing and commercializing traditional Chinese medicine, biological drugs and chemical drugs. Tasly Biopharmaceuticals Co., Ltd. is a subsidiary of Tasly Pharmaceutical and a leading innovative biopharmaceutical company in China with integrated commercialization platform spanning the entire biologics value chain.
Tasly Biopharma with its headquarter in Shanghai focuses on the development of biologic drugs in the therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. Our target therapeutic areas are among the largest and fastest growing therapeutic areas in China, where biologics are expected to become one of the key growth drivers.
Pro-UK is an innovative biologics drug manufactured and commercialized by Tasly Biopharma, which is indicated for STEMI thrombolysis with a better efficacy and safety profile than alteplas. In addition to Pro-UK, we have a rich biopharmaceutical products under development.
Tasly has collaborated with various overseas companies, including Transgene, Pharnext, EA, Eli Lilly, APbio, etc.. Some of the assets from collaboration have been successfully transferred to China, and clinical trials have been initiated.
Tasly is actively looking for partnerships on clinical-stage to marketed assets, through straight licensing, co-development, strategic investment, etc. in the abovementioned disease areas to bring the asset to China market.